-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Vericel Co. (NASDAQ:VCEL) Shares Acquired by GW&K Investment Management LLC
Vericel Co. (NASDAQ:VCEL) Shares Acquired by GW&K Investment Management LLC
GW&K Investment Management LLC lifted its holdings in shares of Vericel Co. (NASDAQ:VCEL – Get Rating) by 169.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 907,249 shares of the biotechnology company's stock after buying an additional 571,139 shares during the quarter. GW&K Investment Management LLC owned approximately 1.93% of Vericel worth $34,676,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. State Street Corp increased its position in shares of Vericel by 12.3% during the fourth quarter. State Street Corp now owns 2,809,660 shares of the biotechnology company's stock worth $110,420,000 after purchasing an additional 307,755 shares in the last quarter. Conestoga Capital Advisors LLC raised its stake in Vericel by 54.7% during the first quarter. Conestoga Capital Advisors LLC now owns 2,596,810 shares of the biotechnology company's stock worth $99,250,000 after purchasing an additional 918,299 shares during the period. Fisher Asset Management LLC raised its stake in Vericel by 18.9% during the fourth quarter. Fisher Asset Management LLC now owns 1,236,675 shares of the biotechnology company's stock worth $48,601,000 after purchasing an additional 196,635 shares during the period. Geode Capital Management LLC raised its stake in Vericel by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 810,974 shares of the biotechnology company's stock worth $31,871,000 after purchasing an additional 10,108 shares during the period. Finally, New York State Common Retirement Fund raised its stake in shares of Vericel by 9.3% in the 1st quarter. New York State Common Retirement Fund now owns 785,567 shares of the biotechnology company's stock valued at $30,024,000 after acquiring an additional 66,771 shares during the period.
Get Vericel alerts:Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the stock. BTIG Research reduced their price target on shares of Vericel from $45.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, July 18th. Truist Financial cut their price target on Vericel to $33.00 in a research note on Friday, July 22nd. One investment analyst has rated the stock with a sell rating and three have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $37.33.
Vericel Price Performance
Shares of NASDAQ VCEL opened at $29.84 on Tuesday. Vericel Co. has a 1-year low of $22.42 and a 1-year high of $60.24. The company has a market cap of $1.41 billion, a PE ratio of -82.89 and a beta of 1.98. The stock has a fifty day moving average price of $27.11 and a 200 day moving average price of $31.61.Vericel Company Profile
(Get Rating)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.
Recommended Stories
- Get a free copy of the StockNews.com research report on Vericel (VCEL)
- Home Depot, Lowe's On Track To Grow 2022 Earnings
- Could Smaller be Better for Investors in Norwegian Cruise Lines?
- Walmart Or Target: Which Is The Stronger Stock?
- Can Etsy Continue to Thrive After the Pandemic?
- Volume Surges Spark Turnarounds for These 3 Stocks
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
GW&K Investment Management LLC lifted its holdings in shares of Vericel Co. (NASDAQ:VCEL – Get Rating) by 169.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 907,249 shares of the biotechnology company's stock after buying an additional 571,139 shares during the quarter. GW&K Investment Management LLC owned approximately 1.93% of Vericel worth $34,676,000 as of its most recent SEC filing.
GW&K Investment Management LLC在最近提交给美国证券交易委员会(Securities and Exchange Commission,简称:美国证券交易委员会)的13F文件中称,该公司第一季度将持有的Vericel Co.股票增持了169.9%。该公司在本季度额外购买了571,139股后,拥有这家生物技术公司的907,249股股票。截至最近提交的美国证券交易委员会申请文件,GW&K投资管理公司拥有Vericel约1.93%的股份,价值34,676,000美元。
Other large investors have also made changes to their positions in the company. State Street Corp increased its position in shares of Vericel by 12.3% during the fourth quarter. State Street Corp now owns 2,809,660 shares of the biotechnology company's stock worth $110,420,000 after purchasing an additional 307,755 shares in the last quarter. Conestoga Capital Advisors LLC raised its stake in Vericel by 54.7% during the first quarter. Conestoga Capital Advisors LLC now owns 2,596,810 shares of the biotechnology company's stock worth $99,250,000 after purchasing an additional 918,299 shares during the period. Fisher Asset Management LLC raised its stake in Vericel by 18.9% during the fourth quarter. Fisher Asset Management LLC now owns 1,236,675 shares of the biotechnology company's stock worth $48,601,000 after purchasing an additional 196,635 shares during the period. Geode Capital Management LLC raised its stake in Vericel by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 810,974 shares of the biotechnology company's stock worth $31,871,000 after purchasing an additional 10,108 shares during the period. Finally, New York State Common Retirement Fund raised its stake in shares of Vericel by 9.3% in the 1st quarter. New York State Common Retirement Fund now owns 785,567 shares of the biotechnology company's stock valued at $30,024,000 after acquiring an additional 66,771 shares during the period.
其他大型投资者也改变了他们在该公司的头寸。道富银行在第四季度增持了Vericel股票的头寸12.3%。道富集团目前持有这家生物技术公司2,809,660股股票,价值110,420,000美元,此前该公司在上个季度又购买了307,755股。Conestoga Capital Advisors LLC在第一季度将其在Vericel的持股增加了54.7%。Conestoga Capital Advisors LLC现在拥有这家生物技术公司2,596,810股股票,价值99,250,000美元,在此期间又购买了918,299股。Fisher Asset Management LLC在第四季度将其在Vericel的持股增加了18.9%。Fisher Asset Management LLC现在拥有这家生物技术公司1,236,675股股票,价值48,601,000美元,在此期间又购买了196,635股。Geode Capital Management LLC在第四季度将其在Vericel的持股增加了1.3%。Geode Capital Management LLC现在拥有这家生物技术公司810,974股股票,价值31,871,000美元,在此期间又购买了10,108股。最后,纽约州共同退休基金在第一季度将其在Vericel的股份增加了9.3%。纽约州共同退休基金现在拥有这家生物技术公司785,567股股票,价值300,024,000美元,在此期间又购买了66,771股。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
A number of equities research analysts have recently issued reports on the stock. BTIG Research reduced their price target on shares of Vericel from $45.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, July 18th. Truist Financial cut their price target on Vericel to $33.00 in a research note on Friday, July 22nd. One investment analyst has rated the stock with a sell rating and three have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $37.33.
一些股票研究分析师最近发布了关于该股的报告。BTIG Research将Vericel的股票目标价从45.00美元下调至34.00美元,并在7月18日星期一的一份研究报告中设定了该股的“买入”评级。7月22日,Truist Financial在一份研究报告中将Vericel的目标价下调至33.00美元。一名投资分析师对该股的评级为卖出,三名分析师对该公司的评级为买入。根据MarketBeat的数据,该股的普遍评级为“适度买入”,平均目标价为37.33美元。
Vericel Price Performance
Vericel性价比
Vericel Company Profile
Vericel公司简介
(Get Rating)
(获取评级)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.
Vericel公司是一家商业阶段的生物制药公司,在美国从事运动医学和严重烧伤护理市场的细胞疗法的研究、开发、制造和分销。该公司销售自体细胞治疗产品,包括用于修复有症状的膝部单个或多个全层软骨缺陷的自体细胞化支架产品Maci,以及用于治疗成人和儿童深真皮或全面烧伤患者的永久性皮肤置换人道主义使用设备Epicel。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Vericel (VCEL)
- Home Depot, Lowe's On Track To Grow 2022 Earnings
- Could Smaller be Better for Investors in Norwegian Cruise Lines?
- Walmart Or Target: Which Is The Stronger Stock?
- Can Etsy Continue to Thrive After the Pandemic?
- Volume Surges Spark Turnarounds for These 3 Stocks
- 免费获取StockNews.com关于Vericel的研究报告(VCEL)
- 家得宝,Lowe‘s有望在2022年实现收益增长
- 对挪威邮轮公司的投资者来说,更小的规模会更好吗?
- 沃尔玛和塔吉特:哪只股票更强?
- 在大流行之后,Etsy能否继续蓬勃发展?
- 这3只股票成交量飙升,火花回升
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
接受Vericel Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Vericel和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧